Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Cystatins; Vancomycin

Criteria

Inclusion Criteria:

• Hospitalized in one of three intensive care units at Mayo Clinic in Rochester, Minnesota

• Suspected or documented gram-positive infection

• Prescribed IV vancomycin at a consistent dose and scheduled with 8, 12, or 24 hour Vancomycin dosing interval

Exclusion Criteria:

• Vulnerable population

• Received greater than 1 dose of Vancomycin in the 96 hours before ICU admission

• Baseline glomerular filtration rate (GFR) of less than 20 milliliters/minute

• Undergoing renal replacement therapy

• Body mass index > 40kg/m2

• Weight < 40kg